Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Resolvyx to Launch Trial for Dry Eye Treatment
RxTrials Institute Drug Pipeline Alert
Nov. 26, 2008 | Vol. 6 No. 48
Resolvyx to Launch Trial for Dry Eye Treatment
Resolvyx Pharmaceuticals will begin a Phase I/II study using RX-10045 to treat dry eye.
The trial will be a placebo-controlled study in 200 patients with moderate-to-severe dry eye. The company said it will start the study before the end of the year.
The product is an isopropyl ester pro-drug of the company’s Resolvin compound, RX-10008. Preclinical studies have shown the compound to be effective in preventing the harmful effects of dry eye and restoring healthy cell function.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.